178 related articles for article (PubMed ID: 22314523)
1. Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Vanpouille C; Lisco A; Introini A; Grivel JC; Munawwar A; Merbah M; Schinazi RF; Derudas M; McGuigan C; Balzarini J; Margolis L
Antimicrob Agents Chemother; 2012 May; 56(5):2604-11. PubMed ID: 22314523
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
3. A new antiviral: chimeric 3TC-AZT phosphonate efficiently inhibits HIV-1 in human tissues ex vivo.
Vanpouille C; Khandazhinskaya A; Karpenko I; Zicari S; Barreto-de-Souza V; Frolova S; Margolis L; Kochetkov S
Antiviral Res; 2014 Sep; 109():125-31. PubMed ID: 25010891
[TBL] [Abstract][Full Text] [Related]
4. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Lisco A; Vanpouille C; Tchesnokov EP; Grivel JC; Biancotto A; Brichacek B; Elliott J; Fromentin E; Shattock R; Anton P; Gorelick R; Balzarini J; McGuigan C; Derudas M; Götte M; Schinazi RF; Margolis L
Cell Host Microbe; 2008 Sep; 4(3):260-270. PubMed ID: 18779052
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase.
Tchesnokov EP; Obikhod A; Massud I; Lisco A; Vanpouille C; Brichacek B; Balzarini J; McGuigan C; Derudas M; Margolis L; Schinazi RF; Götte M
J Biol Chem; 2009 Aug; 284(32):21496-504. PubMed ID: 19509419
[TBL] [Abstract][Full Text] [Related]
6. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.
Vanpouille C; Lisco A; Derudas M; Saba E; Grivel JC; Brichacek B; Scrimieri F; Schinazi R; Schols D; McGuigan C; Balzarini J; Margolis L
J Infect Dis; 2010 Feb; 201(4):635-43. PubMed ID: 20085496
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
8. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
9. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro.
Bourinbaiar AS; Coleman CF
Arch Virol; 1997; 142(11):2225-35. PubMed ID: 9672588
[TBL] [Abstract][Full Text] [Related]
10. Acyclovir: a new use for an old drug.
Vanpouille C; Lisco A; Margolis L
Curr Opin Infect Dis; 2009 Dec; 22(6):583-7. PubMed ID: 19726982
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
[TBL] [Abstract][Full Text] [Related]
12. N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
Yap SH; Herman BD; Radzio J; Sluis-Cremer N; Tachedjian G
J Acquir Immune Defic Syndr; 2012 Oct; 61(2):153-7. PubMed ID: 22743599
[TBL] [Abstract][Full Text] [Related]
13. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z
Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.
Xu W; Wang Q; Yu F; Lu L; Jiang S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):1-6. PubMed ID: 24977378
[TBL] [Abstract][Full Text] [Related]
15. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs.
Uckun FM; Qazi S; Venkatachalam TK
Arzneimittelforschung; 2005; 55(4):223-31. PubMed ID: 15901046
[TBL] [Abstract][Full Text] [Related]
16. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
[TBL] [Abstract][Full Text] [Related]
17. Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.
Vanpouille C; Lisco A; Grivel JC; Bassit LC; Kauffman RC; Sanchez J; Schinazi RF; Lederman MM; Rodriguez B; Margolis L
Clin Infect Dis; 2015 Jun; 60(11):1708-14. PubMed ID: 25740794
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Schinazi RF; Mellors J; Bazmi H; Diamond S; Garber S; Gallagher K; Geleziunas R; Klabe R; Pierce M; Rayner M; Wu JT; Zhang H; Hammond J; Bacheler L; Manion DJ; Otto MJ; Stuyver L; Trainor G; Liotta DC; Erickson-Viitanen S
Antimicrob Agents Chemother; 2002 May; 46(5):1394-401. PubMed ID: 11959574
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.
Glushakova S; Dubrovsky L; Grivel J; Haffar O; Bukrinsky M
Antiviral Res; 2000 Aug; 47(2):89-95. PubMed ID: 10996396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
